Tryton Medical Enrolls First Patient in the EXTENDED Access Registry A Single Arm Study Designed to Support FDA Submission for US Approval

Durham, N.C. – July 28, 2014Tryton Medical, Inc., the leading developer of stents to treat bifurcation lesions, announced that the first patient has been enrolled in the EXTENDED Access Registry (Tryton IDE XA registry), a single arm study of its Tryton Side Branch Stent. The Tryton IDE XA registry is designed to support FDA submission for US approval and is expected to enroll 133 patients from Europe and the United States. Indulis Kumsars, M.D. of P. Stradins University Hospital, Latvian Centre of Cardiology enrolled the first patient.

Read More

Candid Advice For Cash-Strapped Startups From A Biotech Venture Capitalist

By Josh Baxt, Exclusive Story

July 21, 2014

In a sense, Niall O’Donnell, Ph.D., and his colleagues at RiverVest Venture Partners run a biomedical adoption agency. They track down innovative discoveries, help raise them for a while and then find a good home, either at a pharmaceutical company or through public markets.

For cash-strapped startups, this represents an opportunity, but they need to understand the rules. RiverVest is trying to build companies in five years or less, and that means having excellent IP and a collaborative team to take it towards the finish line.  Read More


Read More

ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients with Hyperkalemia

Company expects to announce top-line results late Q3 or early Q4 2014

Coppell, Texas – July 14, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has completed enrollment in ZS004, its second Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate),

Read More

Otonomy Files Registration Statement for Proposed Initial Public Offering

SAN DIEGO, July 14, 2014 /PRNewswire/ – Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.

Read More